ProQR secures FDA fast track designation for QR-010 to treat Cystic Fibrosis
Fast Track designation is granted by FDA to drugs that are under development for serious conditions and have the potential to fulfill an unmet medical need. It was
Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of zalsupindole (DLX001), an orally bioavailable neuroplastogen.
With the new indication, patients with moderate to severe Alzheimer's disease, who are currently stabilized on Aricept, donepezil hydrochloride (10 mg), can now start combination therapy directly with
The LIBERTY study will evaluate the effects of ubenimex added to current standard of care in patients with pulmonary arterial hypertension (PAH). Despite multiple approved vasodilator therapies, PAH